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Abstract 
 
Background  
Tumor surgery is a great challenge to surgeons. Due to their disseminated characteristic, the 
small and varied foci and blurred margins often evade surgeon’s unaided eyes. Unfortunately, 
surgeons have to rely mainly on preoperative images and their experience. No effective 
method is available that can provide real-time reference. Based on targeted fluorescence con-
trast agents, we are developing an intraoperative imaging system (surgical goggle) for identi-
fying locations and margins of tumors. 
Method 
Tumor targeted MuCC49-Cy7 is injected into a female athymic nude mice. We use light at a 
near infrared (NIR) range (710 – 760nm) to excite the fluorophore. An ICG filter (810-875nm) 
is used to collect fluorescence from MuCC49-Cy7 in vivo. Also, non-fluorescence image is 
acquired immediately after the fluorescence image with the illumination of light at longer 
wavelength. Two images are processed, merged then sent to a Head Mounted Display (HMD, 
vision goggle) for virtual reality display. To validate the accuracy of the system, we use sur-
gical goggle to perform mice anatomy and visualize fluorescence in vitro. 
Result 
The emission fluorescence is not detectable with bare eyes since it is in the NIR range that 
provides deeper penetration. However, with the help of surgical goggle, we are able to clearly 
identify locations and margins of tumors on the mice. At the 1st day after IV injection of 
MuCC49-Cy7, we can visualize dispersive fluorescence. At the 3rd day after the injection, 
fluorescence mainly accumulates at tumor sites. Mice anatomy validates that the merged im-
age correctly delineate tumors. 
Conclusion 
Our surgical goggle can provide real-time, intraoperative reference during surgery. It is a ro-
bust and reliable method for segmenting and subsegmenting tumor. 
 
Introduction 
 
Accurate assessment of surgical resection margins and recognition of occult metastatic 
disease are important oncologic principles in cancer surgery. [1, 2]Currently utilized modali-
ties of cancer detection and imaging focus primarily on preoperative image acquisition and 
may not specifically target the cancer cell environment.  While preoperative imaging is help-
ful, it fails to provide the surgeon with real-time, cancer-specific information that may be 
critical for decision-making in the operating room. The ultimate need to bridge these gaps in 
cancer detection and imaging remains a significant challenge for cancer surgeons, and once 
overcome, such advancements will ultimately revolutionize the intraoperative applications of 
the cancer-specific technologies for cancer surgery.   
We are developing a wearable surgical navigation system for intraoperative detection of 
resection margin and occult disease during cancer surgery. Major function is that the surgical 
navigation system with tumor-specific antibody-fluorophore conjugate is able to provide the 
Fig. 1 Process of intraoperative guidance tumor surgery 
surgeon with intraoperative, real-time information to accurately assess surgical resection 
margins and precisely locate occult disease.  Also, the surgeons can also assess the resection 
specimen intraoperatively. This system is tested on phantoms and animal models. 
 
Method 
 
 1. Disease markers: HuCC49∆CH2 antibody 
 Several biomolecular markers are available for cancer target. As an example, Mono-
Colonal antibodies (trastuzumab, etc) target tissue markers and involve in tumor growth and 
metastasization (EGFR, C-erB-2, VEGF).  It is reported that ECD HER2-neu, p53 and nu-
cleophosmin antibodies seem to be suitable candidates for different associations. [3] These 
are used for breast cancer target. For different cancers, there is always a specialized over-
expression and corresponding antibody for targeting. We uses CC49, an antibody against tu-
mor-associated glycoprotein, TAG-72 which is an antigen expressed on the majority of hu-
man adenocarcinomas, such as breast, ovarian, colorectal and other carcinomas, as our dis-
ease marker. In previous studies, TAG-72 targeted HuCC49CH2-Cy7 is fabricated by conju-
gating humanized CC49 monoclonal antibody (HuCC49CH2) with Cy7 and tested it on fe-
male athymic nude mice with colorectal tumors[4]. We tested our HuCC49CH2-ICG as bio-
marker for tumor detection.  
 2. Imaging markers: HuCC49∆CH2 with 
ICG derivative  
 CC49 is an antibody which against tumor-
associated glycoprotein, TAG-72, an antigen ex-
pressed on the majority of human adenocarci-
Fig. 2 HuCC49∆CH2-ICG derivative conjugate 
 
nomas, such as breast, ovarian, colorectal, and other carcinomas.  
 ICG-ATT is an FDA approved fluorescent dye ICG derivative with strong absorption at 
765 nm[5-8]. As shown in Fig. 2, HuCC49∆CH2 is readily labeled with ICG-ATT by acylating 
the primary amino group of the antibody with optimal molar ratio of ICG-ATT to antibody 
(8:1) to give maximum fluorescence [6]. ICG-ATT (0.5 mg) will be prepared in 200µl di-
methylformamide (DMF) and gradually added to the antibody solution with stirring for 90 
minutes. The conjugated antibody will be purified with a PD-10 column. Absorbance of la-
beled antibody will be measured at 786 nm to determine the concentration of the solution. We 
conjugate Cy7 with the disease-specific biomarker.  Cy7 is a derivative of ICG with an ab-
sorption peak at 730 nm. The peak falls into the near infrared wavelength range, enabling 
thick tissue imaging and tomography. Our colleague has successfully fabricated and pub-
lished the result[4]. 
 3. Hardware and software platform 
Fig. 3 shows hardware design of 
our prototypic system. It is built on a 
vision goggle platform (Personal 
Cinema System, Headplay Canada 
Inc). Superbright LEDs (Super Bright 
LEDs Inc.) are integrated with the 
goggle or used as handheld probe. RGB camera (QuickCam® Pro 9000, Logitech) is in-
stalled on the vision goggle. A long pass filter on the camera collects fluorescence while 
eliminating interference from the excitation light. Also, non-fluorescence background image 
is acquired to provide background reference. The system is driven by the National Instrument 
DAQ-6210. 
Fig. 3 Prototypical surgical goggle system 
 
Excitation and background light illuminate by turns while the camera takes fluores-
cence and background image. The fluorescence image is acquired by thresholding and then 
superimposed on the grayscale background 
image. The whole process is showed in Fig. 4. 
 4. Benchtop test design 
To test the feasibility and reliability of 
the system, we prepare a tissue simulation 
phantom with embedded simulation tumor. 
The tissue is made of gelatin mixed with red 
non-fluorescence dye. To better mimic disseminated characteristic of human tissue, we add 
white powder. Texas Red (central excitation wavelength 596, emission 613) blended with 
gelatin is used to simulate antibody-conjugated fluorophore accumulated on the tumor. 4 non-
fluorescence simulation benign tissues are placed around the tumor. Another layer of tissue is 
placed and covered the top. The configuration of the phantom is showed in Fig. 5.  
A 610nm long pass filter is integrated with the camera. 
In test set I, excitation lights source is a green LED (central 
wavelength 535) with Lambert beam pattern since it can 
provide robust fluorescence without overwhelming the light 
filter. A red LED with central wavelength at 635nm and 
Lambert beam pattern is used as background light. Image 
can be acquired by handholding the excitation light and 
scanning the phantom. 
In test sets II, excitation lightsource is by a handheld green laser pointer (central wave-
length 535 nm). In this set, more homogeneous illumination can be reached. 
 5. Animal model 
Fig. 4 Schematic of image processing 
 
Fig. 5 Configuration of the phantom 
The surgical goggle system discussed above is validated on the animal model. A xenograft 
colonel cancer mouse is generated from human colon cancer cells LS174T since they have high 
levels of TAG-72. To prepare these models, 107 tumor cells in matrigel medium (100µl) is in-
jected subcutaneously into NU/NU nude mice.  Tumor is allowed to grow for two weeks, with 
tumor volumes measured twice per week. IV injection of HuCC49-Cy is performed one day 
before surgery. After 3 days inspection, tumor is surgical removed with image-guidance by the 
proposed surgical goggle and with the direct injection of antibody-fluorophore conjugate. At 
the end of the experiment, the animal is necropsied and organs is collected for histological and 
post-resectional imaging in order to compare the outcomes of five subgroups. 
 
Result 
 
1. Benchtop test result 
The test set I demonstrates that if the excitation light illuminated the tumor, the output 
image will show a red area imposed on the background, indicating the tumor with fluores-
cence. If the excitation does not illuminate the tumor but benign tissues, only background im-
age will be displayed. 
In test set II, the laser pointer will give more stable illumination than that in test set I. 
Fig. 6 Bentop test result for test set I. (Left) tumor under illumination; (Right) non-tumor under illumination. 
 
The first image shows the tumor. The second image shows a small spot on benign tumor due 
to the strong illumination overwhelm the light filter. 
2. Animal test result 
 
After IV injection of HuCC49-Cy7, fluorescence images were acquired after 24 hours 
and 72 hours (excitation: 730nm, emission: 770nm). MuCC49-Cy7 successfully targeted the 
tumor. From the images in Fig. 8, tumor location and boundary can be directly visualized. 
 
Discussion 
 
Fig. 7 Benchtop test result for test set II. (Left) tumor under illumination; (Right) non-tumor under illumination. 
Fig. 8 Sample images that can be visualized from the surgical goggle. (a) The 1st day after IV injection of 
MuCC49-Cy7. (b) The 3rd day after IV injection of MuCC49-Cy7 
 
Disseminate characteristic of tumors makes it a big challenge to the surgeons when per-
forming cancer surgery. However, visualization and properly deal with small foci are of great 
importance for cancer surgery. We have demonstrated that our targeted fluorescence bio-
marker can help visualize lesions that are not applicable in traditional white light imaging.  
One advantage of our technique is that binding efficiency of HuCC49 is high on colonel 
cancer, making better fluorescence efficacy. After binding, the tumor cells take up the fluoro-
phore and the rest will go with the circulation, taken and cleared by liver. Those accumulated 
in the live will not influence the fluorescence in the colonel cancer. Therefore, the distribution 
of this contrast agent will not influence its application. 
There are still potential issues that we are working on. The first is that it usually takes 
time to collect enough fluorescence. This time will cause lag between image frames. The sur-
geons may feel dizziness when wearing the surgical goggle. Potential solution can be ac-
quired by our developing fluorescence enhancement technique. By encapsulating fluores-
cence in a nanoparticle, we can deliver more fluorophore to the target under the condition of 
the same binding efficiency. This will greatly reduce the exposure time for acquiring fluores-
cence image and increase frame rate of the fused image. 
Also, frame rate can be increase to provide more natural feedback for surgeons. For this 
purpose, stronger illumination is needed. In our experiment, we use laser pointer for excita-
tion, this will generate stronger fluorescence and reduce exposure time. Also, we can increase 
the background illumination. Also, we can increase the aperture of the camera, allowing more 
light to enter the camera. 
Another potential issue is caused by heterogeneous illumination of excitation light. Cur-
rently, static threshold is used to abstract fluorescence image. Therefore, the distance between 
the light source and the tissue, the incident angle may cause different illumination and fluo-
rescence strength. To solve this problem, laser pointer will provide better result because laser 
is more collimated without scattering beam pattern. Also, our next step is to develop a dy-
namic algorithm for threshold. 
 In conclusion, wse believe that surgical goggle is a good concept and is quite potential 
in the future. We hope that in the future, we and develop a robust, fast and safe intraoperative 
surgical system for cancer surgery. 
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